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The non-integrin laminin receptor (LAMR1/RPSA) and galectin-3 (Gal-3) are
multi-functional host molecules with roles in diverse pathological processes,
particularly of infectious or oncogenic origins. Using bimolecular fluorescence
complementation and confocal imaging, we demonstrate that the two proteins
homo- and heterodimerize, and that each isotype forms a distinct cell surface
population. We present evidence that the 37 kDa form of LAMR1 (37LRP) is
the precursor of the previously described 67 kDa laminin receptor (67LR),
whereas the heterodimer represents an entity that is distinct from this molecule.
Site-directed mutagenesis confirmed that the single cysteine (C173) of Gal-3 or
lysine (K166) of LAMR1 are critical for heterodimerization. Recombinant Gal-3,
expressed in normally Gal-3-deficient N2a cells, dimerized with endogenous
LAMR1 and led to a significantly increased number of internalized bacteria
(Neisseria meningitidis), confirming the role of Gal-3 in bacterial invasion. Con-
tact-dependent cross-linking determined that, in common with LAMR1, Gal-3
binds the meningococcal secretin PilQ, in addition to the major pilin PilE. This
study adds significant new mechanistic insights into the bacterial–host cell inter-
action by clarifying the nature, role and bacterial ligands of LAMR1 and Gal-3
isotypes during colonization.2. Introduction
The non-integrin laminin receptor (LAMR1), also commonly referred to as ribo-
somal protein SA (RPSA), is a highly conserved multi-functional protein that
has been localized to the cell surface, the cytosol, the 40S ribosomal subunit
and, in histone, chromatin and membrane-associated complexes in the nucleus
[1–6]. We recently demonstrated that the three major aetiological agents of
bacterial meningitis, Neisseria meningitidis, Streptococcus pneumoniae and Haemo-
philus influenzae, engage LAMR1 on the surface of human cells via specific
surface ligands [7]. LAMR1 has also been identified as the surface receptor
for the Escherichia coli K1 toxin Cfr1, a number of viruses, and the cellular prion
protein [8–13]. LAMR1 also has roles in cell viability, adhesion and motility.
Importantly, elevated LAMR1 expression correlates stronglywith increased inva-
siveness and metastatic potential of cancer cells [2,5,14–16]. Taken together,
LAMR1 has important functions in diverse pathological processes, particularly
of infectious or oncogenic origins.
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64 copies, although these are predominantly pseudo-genes; it
is unclear how many functional copies there are [17], but one
or more active genes encodes the 37 kDa ‘precursor’ protein
(37LRP), which migrates at 37–45 kDa on SDS–PAGE gels.
A proportion of 37LRP migrates to the cell surface, where it
is thought to ‘mature’, possibly via dimerization and/or post-
translational modification, into the 67 kDa high-affinity
receptor (67LR), which migrates at 60–67 kDa on SDS–
PAGE gels. The transition from 37LRP to 67LR has never
been directly demonstrated, however. It is the 67LR isoform
that is thought to act as the receptor for laminin and/or
other substrates including elastin or collagen [2,18–21],
although the 37LRP isoform has also been suggested to
have laminin-binding properties [18,22]. A 120 kDa form of
the protein has also been described, but its nature, identity
and relationship to 37LRP is unknown [23,24].
37LRP has also been suggested to associate with the
b-galactoside-binding lectin galectin-3 (Gal-3), previously
known as the 31 kDa human laminin-binding protein
(HLBP31), to form a composite receptor for molecules includ-
ing laminin [23]. Indeed, a heterodimer containing 37LRP
and a protein carrying one or more galectin-3 epitopes
has been proposed as the basis for 67LR [23]; this has given
rise to confusion in the literature between the homo- and
heterodimers. Evidence for heterodimerization has so far been
circumstantial, based primarily on (i) the cross-reactivity of
anti-Gal-3 antibodies with a 67 kDa protein [23], (ii) that Gal-3
and a 67 kDa protein can be co-eluted from laminin affinity col-
umns by lactose, galactose and N-acetyl-lactosamine [25], and
(iii) pre-treatment of laminin with b-galactosidase abolishes
the interaction of the 67 kDa molecule and Gal-3 with laminin
[25]. Nevertheless, 67LR is observed in Neuro 2a (N2a) cells,
which do not express Gal-3, suggesting that 67LR and
37LRP–Gal-3 heterodimer exist as distinct, but potentially
coexisting cell surface populations.
Together with galectin-1, Gal-3 is an important mediator
of inflammation, and is involved in recruitment of neutro-
phils, bacterial recognition and activation of the phagocytic
respiratory burst [26]. Gal-3 is the only chimera-type galectin,
and occurs mainly as a monomer in solution [27]; it also
self-associates on surfaces and, upon binding to divalent
ligands, into homodimers or pentamers [28–30]. Gal-3 has
one C-terminal 135-amino acid carbohydrate recognition
domain (CRD) that is responsible for binding the b-galactoside
moiety of mono- or oligosaccharides on several host molecules,
including the b-galactosides and the poly-N-acetyl-lactosa-
mine residues of host laminin [31], and structurally similar
microbial molecules including neisserial lipooligosaccharide
(LOS) [32,33]. The N-terminal domain (NTD) of Gal-3 is non-
lectin-binding, but can bind proteins as well as recognizing
the lipid A/inner core region of bacterial lipopolysaccharides
(LPSs) [34]. It is also thought to be responsible for the protein’s
self-association, although Gal-3 self-association in solution via
its CRD has also been described [35].
A fundamental understanding of the nature and functions
of Gal-3 and the multiple isotypes of LAMR1 is central to our
understanding of the diverse pathological processes in which
these proteins play critical roles. LAMR1 and Gal-3 are both
differentially expressed in various cancer cells, and between
them play regulatory roles in a broad range of processes,
including cancer cell growth, transformation, apoptosis,
angiogenesis, adhesion, invasion and metastasis [2,36]. Thedirect relationship between these proteins remains controver-
sial, and is often confusing. As a consequence, our current
lack of understanding of the basic biochemistry, cell biology
and ligand-specificity of the homo- and heterodimers of
37LRP and Gal-3 remains a hindrance to further progress
towards deciphering these important pathological processes.
In this study, we show evidence for the self- and mutual
association of 37LRP and Gal-3, show their distinctive surface
distribution and demonstrate that they target an overlapping
repertoire of surface ligands on N. meningitidis. We pro-
vide the first evidence that, together with LAMR1, Gal-3
expression enhances bacterial host–cell invasion. Our data
clarify much of the confusion relating to LAMR1/Gal-3
monomeric and dimeric isotypes, and will have significant
implications in the fields of infection and cancer biology.3. Results
3.1. Molecular modelling supports the proposed
association of 37LRP and Gal-3
The proposed interaction of 37LRP and Gal-3 was investi-
gated using the ZDOCK server (zdock.umassmed.edu) and
their docking compared with the previously proposed inter-
action of two 37LRP molecules forming a homodimer [18].
ZDOCK has been reported to achieve high predictive accu-
racy on protein–protein docking benchmarks for rigid-body
cases and consistent success in the international protein–
protein docking experiment [37]. The model revealed a
large protein–protein interface between the 37LRP and
Gal-3 subunits, involving several prominent 37LRP residues,
mainly through salt bridges and hydrogen bonds (figure 1).
In the proposed complex between 37LRP and lactose-associ-
ated Gal-3 (figure 1a), four salt bridges are apparent. They
are K166 of 37LRP with D178 and D154 of Gal-3, R80 of
37LRP with D178 of Gal-3, D151 of 37LRP with R151 and
K227 of Gal-3, and D44 of 37LRP with K233 of Gal-3. Hydrogen
bonds between N81 of 37LRP and N180 of Gal-3, N29 of 37LRP
and K233 and E230 of Gal-3, and Y28 of 37LPR and E230 of
Gal-3 are also involved in the interaction (figure 1a). A similar
interaction mode occurs between 37LRP and non-liganded
Gal-3 (figure 1b). Here, K166 in 37LRP also interacts with
D178 and D154 of Gal-3, and S233 of Gal-3 forms a hydrogen
bond with D44 in 37LRP.
Importantly, binding of Gal-3 to the proposed heterodi-
mer interface is incompatible with both homodimer
formation (figure 1c) and laminin binding to at least one of
the four proposed laminin-binding sites of 37LRP, because
the relevant residues (A114, F116 and Y139 for homodimeriza-
tion and F32, E35 and R155 for 37LRP-laminin binding) [38] are
either sterically hindered or implicated in the heterodimer
interaction. In short, our model supports a hypothesis of
the mutual exclusivity of 37LRP homodimerization to form
67LR and 37LRP/Gal-3 heterodimerization for a given
37LRP molecule, while allowing for the possibility that
both homo- and heterodimers could coexist as separate mol-
ecules. It should be noted, however, that the LAMR1 crystal
structure is derived from a truncated protein and the pro-
posed structure of the homodimer is highly speculative;
it is possible that the proposed dimer interface may be an
artefact of crystallization.
Hoechst
37LRP-vYFP
Gal-3 mCherry
merged
(b)
(a)
(c)
(d )
Figure 1. Molecular modelling of 37LRP interaction with galectin-3. (a) Ribbon diagram of the heterodimer interaction of 37LRP with (a) lactose-liganded or
(b) non-lactose-liganded Gal-3. Residues involved in the hypothetical large protein–protein interface are represented with sticks. (c) Ribbon diagram with super-
imposed molecular surface of the homodimer interaction of 37LRP (red) with a second 37LRP (cyan) as proposed by Jamieson et al. [18]. (d ) Fluorescently labelled
recombinant Gal-3 and 37LRP were detected in transiently co-transfected COS7 cells via vYFP or mCherry tags. Cells were fixed at 24 h with 4% paraformaldehyde
without permeabilization and stained with Hoechst.
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To demonstrate cell surface co-localization of Gal-3 and 37LRP,
two independent approaches were adopted. First, COS7 cells
were co-transfected with constructs encoding recombinant
37LRP and Gal-3 proteins fused at their C-terminal ends with
vYFP (YFP) or mCherry, respectively. Both proteins were
successfully expressed and co-localized (figure 1d).
As the data presented in figure 1d could also be consistent
with a cytosolic location of the protein, to demonstrate sur-
face localization human cerebrovascular endothelial cells(hBMECs) were double-labelled for endogenous 37LRP,
67LR and/or Gal-3. Use of a wide range of antibodies with
differing specificities for various isoforms of LAMR1 has
resulted in considerable confusion in the literature. We
selected antibodies with defined specificities as follows:
rabbit IgG polyclonal (IHLR) raised in-house against 37LRP-
derived peptide aa263–282 [7] and the commercially available
mouse IgG2b monoclonal (A7) raised against the 37LRP-
derived peptide aa253–289 were employed to detect 37LRP.
Both recognized an indistinguishable approximately 40 kDa
protein in human hBMECs in immunoblotting experiments
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taining experiments (electronic supplementary material,
figure S1; co-localization coefficient: 81.5%). 37LRP was predo-
minantly cytoplasmic but was also present to a much lesser
extent in the membrane fraction of hBMECs and in the soluble
nuclear fraction (electronic supplementary material, figure S1).
IHLR, but not A7, exhibited very low level cross-reactivity
with an approximately 60 kDa band (possibly 67LR) in the
cytoskeleton-enriched cell fraction of hBMECs.
Thewidely used mouse IgMmonoclonal MLuC5, which is
known to block several LAMR1-mediated functions, exhibited
a distinct immunostaining pattern from the two 37LRP-specific
antibodies and predominantly recognized an approximately
60 kDa protein (presumably 67LR) in hBMEC cellular frac-
tions. This protein was predominantly associated with the
cytoskeletal cell fraction, butwas also present in small amounts
in the membrane and nuclear fractions (electronic supple-
mentary material, figure S1). The commercially available
Gal-3-specific mouse monoclonal (MAb; Mac-2 clone M3/38;
Biolegends) and goat polyclonal (PAb; AF1154; R&D Systems)
antibodies were also employed. Staining of non-permeabilized
hBMEC cells clearly demonstrated the co-localization of Gal-3
(usingMAb)with 37LRP (figure 2a,b), but notwith 67LRon the
cell surface (figure 2c). Similar results were obtained using a
second Gal-3 MAb (clone 9H3.2; Millipore). Cells stained
with anti-Gal-3 PAb and 67LR-specific MLuC5 consistently
demonstrated a significant co-localization of Gal-3-specific epi-
tope(s) with 67LR (more than 90%), consistent with the
existence of a Gal-3-specific epitope associated with the 67LR
molecule [23] (figure 2d). The identity of this epitope is
unknown, but it is not localized to galectin-3 as two indepen-
dent galectin-3-specific monoclonal antibodies do not detect
a protein in association with 67LR. Additionally, COS7 cells
(which exhibit no surface-localized 67LR (electronic sup-
plementary material, figure S2) demonstrated clear surface
co-localization of 37LRP and Gal-3 (figure 2e), suggesting
that 37LRP/Gal-3 heterodimers are distinct from 67LR, a find-
ing which is consistent with the observation that 67LR can be
detected in N2a cells, which do not express Gal-3 [9]. By deter-
mining the co-localization coefficient of 37LRP or 67LR with
Gal-3 (using MAb M3/38) on hBMECs, we observed that
Gal-3 associated with approximately half of the surface-
localized 37LRP (50+5.9%); by contrast, only 9.4+2.1% of
the surface-localized 67LR co-localized with Gal-3 (figure 2k).
3.3. Gal-3 and 37LRP form homo- and heterodimers
To test the hypothesis that 37LRP is capable of forming
homodimers and also heterodimers with Gal-3, as suggested
by our model, we employed a bimolecular fluorescence com-
plementation (BiFC) technique. A fluorescing union is formed
when two separate non-fluorescent YFP subfragments are
brought together by the close association of two intimately
interacting proteins [39]. In addition to the full-length YFP,
its N- or C-terminal domains (Yn and Yc, respectively)
were fused to the C-terminal end of Gal-3 and 37LRP
(figure 3a), and transfected into N2a, hBMECs and COS7
cells (figure 3b–g shows N2a cells). Immunoblot analysis of
host cells (electronic supplementary material, figure S3) con-
firmed transfection and protein expression. Although 37LRP
was readily observed in COS7 cells by fluorescence
microscopy (electronic supplementary material, figure S2)
and immunoblotting (electronic supplementary material,figure S3), no 67LR was observed in these cells, suggesting
that under the experimental conditions tested, 67LR did not
form. As the tagged proteins do not form a higher molecular
mass protein equivalent to 67LR, it is possible that additional
factors may be required subsequent to homodimerization (as
detected by our BiFC experiments) for the maturation into the
SDS-stable 67LR form of the protein, which are not present in
these cells. This would be consistent with the observation that
endogenous 37LRP was apparent in these cells (electronic
supplementary material, figures S2 and S3), whereas 67LR
was not detected. It should also be noted that in cells expres-
sing endogenous 37LRP and 67LR the latter species runs in
SDS–PAGE gels with an apparent molecular mass of
around 60 kDa, which is lower than might be expected of a
homodimer of 37LRP, which has an apparent molecular
mass of around 42 kDa (electronic supplementary material,
figure S1). The most likely explanation for this is that 67LR
is resistant to denaturation in SDS, and thus maintains a
more compact structure than during SDS–PAGE and runs
with a higher electrophoretic mobility.
Cells were examined 24 h post-transfection by confocal
microscopy after fixation without permeabilization. Trans-
fection with full-length YFP-fused proteins (figure 3c,d,
respectively; positive control) resulted in the appearance of
punctate fluorescence;non-transfected cells (figure 3b) exhibited
negligible fluorescence, as did cells transfected with Yn or Yc
constructs alone (figure 5d shows FACS analysis of COS7
cells; see below). Co-transfection of cells with 37LRP–Gal-3,
37LRP-37LRP or Gal-3-Gal-3 (each pair carrying comple-
mentary Ynþ Yc) yielded fluorescent cells, indicating both
homo- and heterodimerization of both molecules (figure 3e–g).
Similar results were observed in COS7 cells, whereas in
hBMEC cells, punctate fluorescence could be observed in cells
co-transfected with 37LRP–Gal-3 or 37LRP-37LRP, while cells
co-transfected with Gal-3–Gal-3 did not fluoresce. The reason
for this is not known. Quantification and statistical analysis of
surface fluorescence of transfected cells, using confocal and
FACS analysis, confirmed the statistical significance of homo-
and heterodimerization of both 37LRP and Gal-3 (figure 5d
shows data for COS7 cells).3.4. Surface 67LR is resilient to siRNA knockdown of
Gal-3 or 37LRP
Gal-3 or 37LRP was knocked down by targeting LGALS3
or RPSA, respectively, in hBMEC cells over a 48 h period
(figure 4). RT-qPCR analysis confirmed the effective and
specific silencing of Gal-3 and 37LRP siRNA treatment at the
level of mRNA (figure 4j). Fixed siRNA-treated cells were
co-stained for either Gal-3 or 37LRP and compared with
untreated or mock siRNA-treated cells. RPSA siRNA-treated
cells exhibited significantly reduced levels of both surface
37LRP and Gal-3 (figure 4c,g), whereas Gal-3 siRNA-treated
cells exhibited significantly reduced surface levels of Gal-3
(figure 4d), but not 37LRP (figure 4i). Approximately 50% of
surface-localized37LRPwasGal-3-associated, and levels of sur-
face-localized Gal-3 were significantly reduced (by approx.
37%) in the presence of 37LRP siRNA (figure 4i), implying
that 37LRP promotes Gal-3 surface localization. It should be
noted, however, that 37LRP is a ribosomal protein and it is
also possible that depressed levels of this protein could
reduce transcription of Gal-3. Surprisingly, in both 37LRP and
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Figure 2. Preferential co-localization of galectin-3 and 37LRP. hBMECs were co-stained with either (a,b) 37LRP or (c,d ) 67LR antibodies (green) in combination with
(a,c) monoclonal (MAb M3/38) or (b,d ) polyclonal (PAb) Gal-3 antibodies (red). (e) COS7 cells were stained with 37LRP and MAb Gal-3 antibodies. Co-localization is
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representative of 2 independent experiments. (k) Co-localization of LRP and 67LR with Gal-3 on the cell body of hBMECs was analysed by ZEN software. Data are
mean+ s.e.m., derived from .50 cells in 2 independent experiments. Data analysed by one-way ANOVA and Tukey test, ***p , 0.0001.
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of 67LR was not significantly different from untreated
(figure 4a,e) or mock siRNA-treated cells (figure 4b,f). Further-
more, overexpression of 37LRP by transfection did not coincide
with increased 67LR (electronic supplementary material,
figure S2). These observations indicate a low turnover of67LR. To further investigate the relationship between expres-
sion of RPSA and the appearance of 37LRP and 67LR cells
were treated with non-targeting siRNA or RPSA siRNA for
48, 72 or 96 h before fixing and analysis by confocalmicroscopy.
37LRP was significantly reduced by 48 h, as previously
observed, and was still significantly reduced by 72 h, although
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37LRP with residue 166 substituted to alanine (white arrow). The mutation of K166 in 37LRP to alanine is predicted to disrupt the interaction between the two
molecules (compare with figure 1a), whereas some (i.e. between R151 and K227 of 37LRP with D151 of Gal-3) are retained. (c) Superimposed structures of lactose-
liganded (yellow) and non-lactose-liganded (blue) Gal-3 complexed with 37LRP highlighting the positions of K166A, R155 and Y139 (white arrows). Other features in
the 37LRP/Gal-3 interface are not shown for clarity. (d ) Following transfection of COS7 cells with the indicated 37LRP and Gal-3 -vYFP, -Yn or -Yc fusion proteins,
cells were harvested and the number of fluorescent cells quantified by FACS and expressed as a percentage of the total number of cells counted. Expression of
37LRP-YFP, Gal-3-YFP and Gal-3C173A-YFP resulted in a significant increase in fluorescent cells compared with -Yn and -Yc control constructs (37LRP: 18.4+ 1.1%
compared with 0.28+ 0.07% and 0.18+ 0.05%; Gal-3: 28.4+ 3.1% compared with 0.19+ 0.04% and 0.21+ 0.03%; Gal-3C173A: 25+ 6.7% compared with
0.21+ 0.07% and 0.26+ 0.12%). Co-transfection of 37LRP-Yn and -Yc, which would form a 37LRP homodimer (37LRP HD), resulted in 10.89+ 0.9% fluorescent
cells, a similar number to cells co-transfected with either 37LRP-Yn and Gal-3-Yc (12.39+ 1.6%) or Gal-3-Yn and Gal-3-Yc (12.65+ 1.4%), which would form a
heterodimer (37LRP/Gal-3 HTD) or self-associated Gal-3 (Gal-3 HD), respectively. Similar results were obtained when Gal-3-Yn and 37LRP-Yc constructs were inves-
tigated. Mutation of C173 on Gal-3 resulted in a significant inhibitory effect on 37LRP/Gal-3 HTD (3.29+ 1.8%; approx. 73% inhibition) and Gal-3 HD formation
(6.5+ 0.9%; approx. 49% inhibition). Co-transfection of Gal-3C173A–Yn and Gal-3C173A–Yc resulted in negligible numbers of fluorescent cells (0.8+ 0.6%)
demonstrating complete disruption of protein–protein interactions under these conditions. Data are mean+ s.e.m. of 3 independent experiments. (e) Binding
of Gal-3 to ELISA wells coated with recombinant 37LRP or its mutant derivatives. The mean value obtained from Gal-3 binding to BSA-coated wells was subtracted
from all data points. ( f ) Flow cytometry analysis of COS7 cells transfected with indicated pairs of BiFC constructs and analysed 36 h post-transfection. Substitution of
LAMR1 lysine 166 with alanine significantly reduced its heterodimerization with Gal-3. Fluorescence intensity was evaluated as a percentage of gated cells. Data
analysed by one-way ANOVA and Tukey test. ****p, 0.0001; *p, 0.05. Error bars ¼ mean of triplicate values on three occasions+ s.e.m.
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had recovered further and were not significantly lower than in
untreated cells (figure 4k). 67LR levels were not significantly
different than in untreated or mock-treated cells by 48 h, as
had previously been observed. However, by 72 h, there was
an approximately 70% reduction in 67LR levels in RPSA
siRNA-treated cells compared with untreated or mock-treated
cells, which was highly significant. By 96 h, 67LR levels were
still significantly depressed in RPSA siRNA-treated cells,
although levels had started to recover by this time.
3.5. Gal-3 residue C173 and 37LRP residue K166 are
implicated in 37LRP–Gal-3 dimerization
The sole cysteine residue of murine Gal-3 (C186, corresponding
to C173 in its human homologue) has been implicated in
Gal-3/Gal-3 homodimerization [40] (figure 5a). We substituted
alanine for C173 (yielding Gal-3C173A), and fused the mutant
molecule toYnandYc.Co-transfectionofCOS7cellswith comp-
lementary Gal-3C173A Yn and Yc pairs resulted in very little
fluorescence, confirming the central role of C173 in homodimer-
ization and the validity of the BiFC approach (figure 5d).
Dimerization of Gal-3C173A with wild-type Gal-3 or wild-type
37LRP was also significantly reduced (figure 5d); the latter
observation suggests a role for C173 in Gal-3/37LRP heterodi-
merization. In contrast, alanine substitution of 37LRP’s two
cysteines (C148 and C163) had no statistically significant effect
on 37LRP cell surface expression cells as measured by FACS
analysis of COS7 cells transfected with the relevant BiFC
constructs (electronic supplementary material, figure S4).
Our molecular model suggested that K166 of 37LRP may
play an important role in the interaction of this molecule
with Gal-3 (figure 1). Substitution of alanine for K166 in
37LRP is predicted to disrupt several interactions between
the two molecules (compare figure 1a and figure 5b; for clarity,
the position of 37LRP K166 is highlighted in the proposed
interaction of 37LRP with superimposed lactose and non-
lactose-liganded Gal-3 shown in figure 5c). To investigate
this, we purified recombinant 37LRP and a 37LRPK166A deri-
vative, and determined their binding to Gal-3 in ELISA
experiments. The ability of the 37LRPK166A derivative to bind
rGal-3 was significantly reduced, confirming the involvement
of this residue in heterodimer formation and supporting the
validity of ourmodel of heterodimerization (figure 5e). By con-
trast, substitution with phenylalanine or alanine, respectively,
of key residues implicated in homodimerization or laminin
binding (Y139 and R155, respectively) [38] had no significant
impact on Gal-3 binding (Y139F), or reduced binding signifi-
cantly but to a much lower degree (R155A; figure 5e). The
involvement of K166 of LRP in binding to Gal-3was confirmed
by BiFC complementation experiments; K166A derivatives of
37LRP fused to either the N- or C-terminal portions of YFP
interacted to a significantly lower degree with their corre-
sponding C- or N-terminal YFP-labelled Gal-3 partners
compared with the wild-type molecules (figure 5f ).
3.6. Gal-3 engages meningococci and potentiates
cellular invasion
Gal-3 has previously been shown to be expressed in splenic
tissue from patients infected with N. meningitidis, but not that
of healthy humans, and co-localization of Gal-3 withmeningococcal colonies on splenic tissue was demonstrated
[33]. Quattroni et al. also showed that Gal-3 binds to the
lactosamine moiety of meningococcal LOS. To determine
whether interactionofmeningococciwithGal-3 couldpotentiate
cellular invasion, N2a cells, which do not express endogenous
Gal-3,were transfectedwith aGal-3-YFP construct prior to infec-
tion with meningococci. Diffuse expression of Gal-3 was
confirmed by confocal microscopy (figure 6a). Expression of
endogenous 37LRP, which co-localized with Gal-3.vYFP on
the cell surface, was also confirmed (figure 6a), confirming that
these cells were an appropriate model to study the role of Gal-
3 in the interaction of meningococci with host cells. Internalized
meningococci were measured using a gentamicin protection
assay after infection of N2a cells transfected with either the
emptyvectorpcDNA3.1 zeo-vYFPor the samevector containing
the Gal-3-YFP construct. Meningococci invaded cells express-
ing Gal-3-YFP at significantly higher levels than those
transfected with the empty vector, or non-transfected cells
(figure 6b) confirming a role for Gal-3 in cellular invasion by
meningococci. In order to confirm these findings in a more
physiologically relevant cell line we knocked down Gal-3
expression by siRNA transfection in hBMEC cells and deter-
mined whether invasion of these cells by meningococci was
affected. Indeed, transfection with Gal-3 siRNA significantly
reduced invasion of these cells by meningococci (strain MC58),
whereas transfectionwith a non-targeting siRNAhad no signifi-
cant effect (figure 6e). Similarly, blockading surface Gal-3
molecules by pre-treating hBMEC cells with polyclonal anti-
Gal3 reduced the susceptibility of these cells to meningococcal
invasion (figure 6f ).
3.7. Neisseria meningitidis binds Gal-3 in a
lipooligosaccharide-dependent and -independent
manner
Quattroni et al. [33] showed that high concentrations (100 mM)
of lactose significantly reduced, but did not abolish, binding
of Gal-3 to meningococci. Similarly, meningococcal mutants
not elaborating the a-chain of LOS showed significantly
reduced, but not completely abolished Gal-3 binding
(figure 6c). Collectively, this suggested the presence of
additional meningococcal Gal-3 receptors. To explore this,
we used lactose-liganded recombinant Gal-3 (Lac–Gal-3) in
further ELISA assays. Lac–Gal-3 was biologically functional,
as determined by its ability to bind 37LRP, N. meningitidis
MC58 and 25 additional isolates, irrespective of their
invasiveness, serotype or country of isolation (electronic sup-
plementary material, figure S5 and table S1). Meningococcal
binding to Lac–Gal-3 was not inhibited by increasing con-
centrations of lactose (up to 150 mM) or by adding a range
of other Gal-3-binding sugars (Lewis X, Lewis Y, core H
type II, galactose and fucose; electronic supplementary
material, figure S6), suggesting that lactose-liganding had
successfully blocked the carbohydrate-dependent (and thus
LOS-dependent) binding capacity of Gal-3.
3.8. Gal-3 and 37LRP target common as well as specific
meningococcal targets
To identify non-LOS meningococcal Gal-3-binding surface
molecules, we employed a re-tagging (a contact-dependent
untreated
n.s.
CF
U
 re
co
v
er
ed
 p
er
 w
el
l *300
200
100
0
mock siRNA Gal-3 siRNA
(e)
untreated
CF
U
 re
co
v
er
ed
 p
er
 w
el
l *150
100
50
0
Gal-3 blocked
( f )
***
*** **
*
**
NT Gal3-YFP MC58 MC58DlgtF DpilQ DpilE DporAYFP
Gal-3 vYFP anti-37LRP co-localization (37LRP and Gal-3)
800
600
400
200
0
1.5
1.0
0.5
0
1.2
1.0
0.8
0.6
0.4
0.2
0
in
te
rn
al
iz
ed
 b
ac
te
ria
 (C
FU
m
l–1
)
O
D
 (4
05
 nm
)
O
D
 (4
05
 nm
)
(a)
(b) (c) (d )
Figure 6. Gal-3 and 37LRP target common as well as specific meningococcal targets. (a) Subcellular localization of Gal-3.vYFP and endogenous 37LRP in transfected
N2a cells. Cells were fixed at 24 h with 4% paraformaldehyde without permeabilization. Fluorescently labelled recombinant Gal-3 was detected via the vYFP tag.
Endogenous 37LRP was detected using IHLR antibody. Co-localization is observed as yellow in merged image with Hoechst 33258 DNA staining (blue). Images are
representative of 2 independent experiments. (b) Gal-3 expression enhances MC58 invasion of N2a cells. N2a cells were transiently transfected with an empty
pcDNA3.1 zeo-vYFP vector alone (YFP), or the same vector containing Gal-3 (Gal-3-YFP). Cells were infected with MC58 for 4 h at a multiplicity of infection of 300
before treatment with 100 mg ml21 gentamycin. NT, non-transfected negative control. Mean+ s.e.m. of at least three separate experiments. Significance was
determined by Student’s t-test. **p , 0.01; ***p, 0.001. (c) Binding of DIG-labelled N. meningitidis MC58 and its isogenic lgtF mutant to immobilized recom-
binant Lac–Gal-3. BSA-coated wells (negative control) were included and their mean value subtracted from those of the test. Mean+ s.e.m. of at least three
separate experiments. Significance was determined by Student’s t-test. ***p, 0.001. (d ) Binding of DIG-labelled N. meningitidis MC58 and its isogenic pilQ, pilE
and porA mutants to immobilized Lac–Gal-3. BSA-coated wells (negative control) were included and their mean value subtracted from those of the test. Mean+
s.e.m. of at least three separate experiments. Significance was determined by Student’s t-test. *p, 0.05; **p , 0.01. (e) hBMEC cells were grown to 60% con-
fluence in 24-well plates were transfected with siRNA oligomers specific for Gal-3, with mock siRNA or left untreated. Post-transfection cells (48 h) were incubated
with 1  107 freshly prepared meningococcal cells (strain MC58) per well. Post-infection cells (4 h) were treated with gentamicin (100 mg ml21) for 1 h to kill
extracellular bacteria. After 1 h incubatin monolayers were disrupted and homogenized with saponin and internalized bacteria enumerated by plating onto chocolate
agar. Compared with non-transfected cells both specific and non-specific siRNA-treated cells demonstrated reduced levels of bacterial invasion, but numbers inter-
nalized into Gal-3 siRNA-treated cells were significantly lower than for non-transfected cells (one-way ANOVA; p, 0.05), whereas mock-transfected cell numbers
were not significantly lower. Bars represent mean of four independent experiments (n ¼ 42) and error bars indicate s.e.m. ( f ) hBMEC monolayers as above were
pre-incubated with either anti-Galectin 3 monoclonal antibody (25 mg ml21) or left untreated for 1 h. Wells were then treated as described above and numbers of
invading meningococci enumerated. Significantly reduced invasion was observed in cells treated with anti-Gal-3 antibodies (unpaired t-test; p, 0.05). Bars
represent the mean of four independent experiments (n ¼ 30) and error bars represent s.e.m.
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Lac–Gal-3 conjugated to a light-activated cross-linker.
Following photoactivation and subsequent exposure to redu-
cing conditions to allow transfer of the reactive biotin moiety
to molecules in close proximity to the Lac–Gal-3, bacteriawere lysed and the biotin-tagged proteins purified with strep-
tavidin-coated magnetic beads as previously described [41].
Extracted biotin-tagged proteins were separated by SDS–
PAGE and identified using MALDI-TOF. This approach
identified PilQ (accession: NMB1812; 82.4 kDa; score:
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as the only Lac–Gal-3 binding meningococcal surface
ligands. PilQ is a conserved outer membrane secretin that is
absolutely required for type IV pilus extrusion [42]. PilE is
the major glycosylated pilin subunit that forms the shaft of
the hair-like and retractile type IV pilus fibre [43,44].
A role for each of these proteins in Lac–Gal-3 binding
by whole bacteria was confirmed by testing the Lac–Gal-3
binding activity of pilQ and pilE mutants. As expected,
MC58 mutants lacking pilE or pilQ showed significantly
reduced Lac–Gal-3 binding when compared with wild-type
(figure 6d ). Mutation of PorA (a 37LRP-binding, surface-
exposed, outer membrane protein employed as a negative
control) had no significant effect on Lac–Gal-3 binding
(figure 6d ). Because PilQ is required for secretion and surface
expression of the PilE-containing fibre, it is not possible from
these data to distinguish between a direct role for PilQ bind-
ing of Gal-3 from an indirect effect owing to the lack of
surface PilE. However, these data show that at least PilE
expression is required for maximal Gal-3 binding.4. Discussion
It is increasingly well established that 37LRP and Gal-3 have
a complex functional relationship and are likely to play colla-
borative roles during physiological and pathological events,
including the interaction of mammalian host cells with patho-
gens [2,45]. On the cell surface, each of these molecules has
been suggested to be both self-associating as well as associat-
ing with each other. However, there is extensive confusion in
the literature regarding the relationship between the 37LRP
species, assumed to represent the monomer, and a 67 kDa
‘mature’ form of the protein, which has been described as
either a homodimer or a heterodimer of 37LRP with Gal-3.
Here, we present evidence for both self- and mutual associ-
ation of both 37LRP and Gal-3. We employed molecular
modelling to visualize the 37LRP–Gal-3 interaction support-
ing previous predictions of mutual association, and further
informed the putative critical interfaces and key residues
involved. BiFC experiments supported the hypothesis that
37LRP and Gal-3 both homo- and heterodimerize, and that
the single cysteine (C173) of Gal-3 (but not the two cysteines
of 37LRP) is critical for these associations, as was previously
shown for the murine Gal-3 molecule’s equivalent residue
C186 [40]. We showed that monomeric 37LRP, its presumed
homodimer 67LR and the 37LRP/Gal-3 heterodimer coexist
as distinct populations on the host cell surface. It is of note
that 67LR has previously been shown to incorporate a
Gal-3-specific epitope that is not present on monomeric
37LRP [23,45]. It is likely that this epitope was responsible
for the observed co-localization of 67-LR with one or more
Gal-3 specific epitopes when a polyclonal antiserum was
employed. We show that this is not due to the presence of
Gal-3 in this complex, however, as it is not detected by two
independent Gal-3-specific monoclonal antibodies. It is poss-
ible that homodimerization results in the creation of a new
epitope that mimics a Gal-3 epitope. Alternatively, the poly-
clonal anti-Gal-3 antiserum may contain 67LR cross-reacting
antibodies that are not specific for Gal-3. The latter possibility
seems unlikely, however, as the polyclonal antiserum
employed was raised against recombinant Gal-3 produced
in E. coli. Gal-3 preferentially associated with 37LRP andrarely (if at all) with 67LR, and knockdown of Gal-3 had
no discernable qualitative or significant quantitative effects
on cell surface 67LR, confirming early models which
suggested that Gal-3 is not a component of 67LR [9,23]. Inter-
estingly, while 37LRP and Gal-3 are shown here to associate,
these proteins dissociate under denaturing SDS–PAGE and
thus cannot represent 67LR, which is known to be resistant
to dissociation in the presence of SDS. Elevated cell surface
67LR is a prognostic marker for metastatic potential in
cancer, yet overexpression of 37LRP by transfection is not
coincident with increased 67LR, which is in line with pre-
vious observations [46–48]. Indeed, the transition of 37LRP
to 67LR has not been conclusively demonstrated to date,
and recombinant 37LRP has never been unambiguously
shown to associate with higher molecular mass isoforms
corresponding to the native 67LR isoform [47]. Our data sup-
port the hypothesis that 67LR is a homodimer of 37LRP, but it
remains a possibility that the ability of 37LRP to homodimer-
ize that we have demonstrated does not represent 67LR, and
further experiments will be required to conclusively settle this
matter. The delayed reduction in 67LR expression after pro-
longed siRNA knockdown of RPSA described here
represents the clearest evidence yet that 67LR is indeed
derived from the smaller protein. It should be born in
mind, however, that another plausible explanation for the
reduction in 67LR after prolonged knockdown of RPSA is
due to a general reduction in protein synthesis that knock-
down of 37LRP, a known ribosomal protein, results in a
more generalized depression of new protein synthesis.
While some 37LRP partitions to the membrane fraction, this
precursor protein is predominantly isolated in soluble cyto-
plasmic cell fractions, where it is known to have a clearly
defined ribosomal association and function. By contrast,
67LR has been clearly demonstrated previously to predomi-
nate in the membrane and, in particular, preferentially
localizes to the environment of ‘lipid raft’ domains and
focal plaques, co-localizing with vinculin and b-actinin
[3,49]. Our demonstration that 37LRP and 67LR are essen-
tially discrete populations implies that the majority of
membrane-associated 37LRP is not lipid-raft-resident or
focal-plaque-associated. While we acknowledge that transfec-
tion and high-level expression of recombinant proteins can
give rise to anomalous protein localization, and that single
amino acid changes can have an effect by altering the overall
conformation of a protein, the observation that our data
are consistent with the in silico modelling data supports our
conclusions based on the BiFC experiments.
Therapeutic strategies based on 67LR currently involve
selective drug targeting, antibodies against 37LRP, polysulfated
glycans and siRNA treatment. Resolving the relationship and
mechanism(s) governing ‘maturation’ of 67LR may provide
new approaches in combinatorial cancer therapy. As interest
in LAMR1 derives from its potential for therapeutic interven-
tion, and the molecule is clearly a pathologically significant
multi-functional protein involved in awide varietyof processes,
assigning roles to differing receptor populations and deter-
mining any potential pleiotropism or functional redundancy
will be critical for effective and selective targeting.
While the precursor–product relationship between 37LRP
and 67LR is widely accepted, the mechanism of 67LR
maturation remains unresolved. As we show that 37LRP is
the predominant Gal-3-associated LAMR1 population, it
is tempting to speculate that Gal-3 may play a regulatory or
LOS
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Figure 7. Illustration of meningococcal binding to host cells using surface ligands. Initial contact mediated by PilC1, which binds its putative receptor, followed by
37LRP/Gal-3-PilE binding, which strengthens the initial contact, and pilus retraction, which brings the two cells closer together. Decametric PilQ on the meningococci
surface binds to both 37LRP and Gal-3, establishes intimate contact, strengthens interactions, and triggers host cell signalling events.
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that the interaction domains for 37LRP homo- and heterodi-
mer formation may overlap, and thus form the basis for
two mutually exclusive LAMR1 cell surface populations. In
support of our hypothesis that a proportion of cell surface
Gal-3 is spatially restricted to 37LRP, previous reports by
Buto et al. [23] showed that treatment of A431 cells with cer-
ulenin, to inhibit 37LRP acylation, resulted in a marked
decrease in detectable Gal-3 and 67 kDa LAMR1 in the
NP-40 soluble membrane fraction [23].
The fact that 37LRP and Gal-3 bind common and separate
antigens in the human host further supports the hypothesis
that the two proteins engage in a joint and mechanistically
synchronized interaction during physiological and pathologi-
cal events. Here, we show that this is paralleled during
bacterial–host cell interactions. Using N. meningitidis as a
model invasive organism that is known to interact with
both Gal-3 and 37LRP [7,33], we showed that both host mol-
ecules are targeted by a common bacterial surface ligand
(PilQ). The latter protein forms a large (960 kDa) homo-dode-
camer complex with an apparent cavity through which the
type IV pilus fibre is exported and retracted [50]. PilE is the
major subunit that forms the shaft of that fibre [43]. PilQ and
PilE remain intimately positioned and are surrounded by
LOS, which is the predominant lipid moiety of the outer leaflet
of the outer membrane. PorA, the other specific meningococcal
ligand for 37LRP, is also a pore-forming outer membrane
protein present in large numbers, and juxtapositioned with
both PilQ and LOS [7,51]. Meningococci, and perhaps other
bacterial pathogens, are likely to have evolved a closely posi-
tioned array of 37LRP- and Gal-3-binding surface ligands,
with consequences for the virulence of these pathogens.
Ligand–receptor interactions may act in concert to enhance
cell–cell intimacy and affinity, and trigger downstream host
cell-signalling and cytoskeletal rearrangements as a prelude
to cellular invasion and tissue penetration [52].
Taken together, these findings lead us to propose a model
for the dynamic and mechanistic interaction of the host and
bacterial surface proteins (figure 7). We propose that upon
entry into the host (mucosa or blood stream), N. meningitidis
would initiate contact with host cell surfaces via the type IVpili, which extend up to several micrometres, and at the tip
may contain the adhesive PilC1 [44]. Retracting pili induces
twitching motility that allows the organism to move over
host cell surfaces against the tide of mucus or blood flow,
until it comes into intimate contact with specific receptors
[53]. Secreted forms of Gal-3 may bind LOS and/or bacterial
protein ligands, a process that is likely to protect the host from
bacterial colonization. However, meningococci may use Gal-3
to enhance its adherence to the host cell surface via Gal-3/
37LRP heterodimerization, or shed the Gal-3–LOS complex
as part of the outer membrane vesicles (which are well
known to be shed continuously). Interestingly, surface Gal-3
is thought to be a negative regulator of the LOS-induced
inflammatory response, and protects the host from endotoxin
shock while also promoting survival of invading bacteria [54].
Similarly, when triggered by specific molecules (e.g. the
LAMR1-binding green tea-derived polyphenol, EGCG), sur-
face LAMR1 is believed to inhibit TLR4 and TLR2 responses
in mouse macrophages [55,56].
Given that both 37LRP and Gal-3 are broadly distributed
in different cellular compartments, their collaborative inter-
action with the meningococcus or its ligands may not be
limited to the cell surface. In the cytoplasm, Gal-3 can bind
to Bcl-2 and inhibit cell apoptosis, and in the nucleus it can
regulate gene transcription [31,57]. Suppression of Gal-3 in
highly malignant human breast carcinoma cells resulted in
reversion of the transformed phenotype and led to the inhi-
bition of tumour growth in immunologically suppressed
mice [58]. Extracellular Gal-3 can bind to cell surface N-gly-
cans and induce monocyte and T-cell apoptosis, which may
help bacterial or tumour cell evasion from the immune
surveillance. Gal-3 can suppress IL-5 production and inhibit
B-lymphocyte differentiation, and increase phagocytosis of
neutrophils. In human monocytes, Gal-3 is chemotactic and
increases calcium influx at high concentrations, whereas at
low concentrations it promotes chemokinesis [59].
In conclusion, we demonstrate the presence of discrete
populations of LAMR1 on the epithelial and endothelial
cell surface. We show that 37LRP can form homodimers
(67LR) as well as heterodimers with Gal-3, which is also
capable of forming homodimers. These surface molecules
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rodegenerative and infectious diseases. 37LRP and Gal-3
target common and specific meningococcal surface ligands,
events that are exploited by the organism to enhance its
adhesion and cell invasion. Our data enhance our under-
standing of the roles of Gal-3 and 37LRP in host cell
biology, which can be exploited for the design of therapeutic
and/or preventive strategies against invasive bacterial and/
or oncogenic diseases. g.org
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5.1. Cell culture
All cells were cultured at 378C, 5% CO2. Human brain micro-
vascular endothelial cells were cultured in endoprime media
(PAA) supplemented with 5% (v/v) fetal bovine serum (FBS),
IGF, bFGF, ascorbic acid, hydrocortisone and heparin,
EGF, VEGF (all from PAA) and 1% antibiotic–antimycotic
solution (v/v) (Gibco). Cells were either P2–15 primary
cells (ScienCell, USA) or immortalized cells at either early
(P10–30) or late (P60–70) passage. Where cells were routinely
cultured on fibronectin, fibronectin-coated T75 flasks were
used (BD Biosciences). Neuro 2a (N2a) mouse neuroblastoma
cells were cultured in Eagle’s minimum essential medium
supplemented with 1% (v/v) antibiotic–antimycotic solution
and 10% (v/v) FBS. COS7 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM, Invitrogen) supplemen-
ted with 1% (v/v) antibiotic–antimycotic solution (Gibco)
and 10% (v/v) FBS. Cell culture medium was changed
every 2 days, and cells were split using trypsin–EDTA
(Gibco) upon reaching 90% confluence.
5.2. Flow cytometry
COS7 cells were grown in six-well plates and detached 24 h
after transfection using cell dissociation solution (Sigma),
washed in PBA buffer (0.5% bovine serum albumin (BSA),
0.5% sodium azide in PBS), resuspended in 0.5% paraformal-
dehyde (PFA) in PBS (Oxoid) and subjected to flow
cytometry using a Coulter Altra flow cytometer. Data acqui-
sition and analysis were performed with WEASEL v. 2.5
software. In each case, 50 000 cells were counted in triplicate
and used to calculate the average BiFC signal intensity+ s.e.
Full-length YFP fluorescence signal was used as the interas-
say reference for maximal fluorescence in each experiment
against which the BiFC signal intensities were compared.
5.3. Immunofluorescence
For confocal analysis, cells were grown on acid-etched glass
12 mm coverslips (SLS) that were coated with 0.1% human
fibronectin (1 ml 2.5 cm22; Sigma) or laminin10 (1 mg cm22;
Millipore) as required. Following any treatments, cells were
fixed with 4% PFA (10 min at RT) and, if required, permeabi-
lized with 0.1% Triton X-100/1% BSA in PBS (5 min at RT).
Following 1 h incubation in PBS/4% BSA to reduce non-
specific binding, coverslips were incubated with primary
antibody(s) either as a cocktail or sequentially, depending
upon predetermined secondary antibody cross-talk: anti-67-
kDa LAMR1 (MAb MLuC5, 1 : 100, Abcam); anti-37-kDa
LAMR1 (PAb IHLR, 1 : 100 [7]; MAb A7, 1 : 250 (Santa CruzBiotech.); anti-Gal-3 (MAb M3/38, 1 : 50 (Biolegends); MAb
9H3.2, 1 : 100 (Millipore); PAb, 1 : 50 (R&D Systems)) in PBS-
T/4% BSA for 1 h. Coverslips were washed three times in PBS
and incubated with conjugated secondary antibody(s): anti-
mouse IgM (Alexa647, 1 : 1500; Alexa488, 1 : 1000); anti-mouse
IgG (Alexa680, 1 : 200); anti-rabbit (Alexa488, 1 : 400; Alexa680
1 : 200); anti-goat (Alexa680, 1 : 200) [1 : 200]; anti-rat
(Alexa647, 1 : 200) all from Molecular Probes, in PBS-T/4%
BSA for 1 h and washed three times in PBS, once in H2-
O. Coverslips were mounted with Prolong Gold anti-fade
with/without DAPI (Invitrogen) and images obtained as sec-
tions, unless stated otherwise, by confocal microscope. For
each experiment, unstained and secondary antibody-alone
samples were processed in parallel to control for non-specific
staining. Additionally, all possible primary/secondary combi-
nations were checked for cross-reactivity and sequential
stainingused as required. For all co-localization studies, samples
stained for localization of each protein individually were pro-
cessed in parallel and, in all cases, the fluorescence of adjacent
channels was monitored for bleed through.
5.4. Confocal microscopy
Images (400–600 nm optical sections) were acquired using a
Zeiss LSM 700 AxioObserver confocal microscope using a
Plan-Apochromat 63/1.40 Oil DIC M27 objective with
ZEN 2009 operating software. Images were processed using
IMAGEJ and Adobe PHOTOSHOP software. Raw data are avail-
able upon request. Co-localization analyses used the ZEN
software function with an FI threshold of 50; the data were
not intensity-weighted. Mean FI data of individual cells or
fields of cells were also obtained using ZEN software.
5.5. Bimolecular fluorescence complementation analysis
BiFC expression constructs were obtained by PCR: cDNA
sequences of human LAMR1 (888 bp) and galectin-3 (725 bp)
were generated with flanking N-terminal EcoRI/Kozak and
C-terminal XhoI restriction sites using the following primer
sequences: for galectin-3, 50-GCGCGAATTCGCCATGGCAGA
CAATTTTTCGCT-30 (forward primer) and 50-GCGCCTCGA
GTATCATGGTATATGAAGCACTGGTG-30 (reverse primer);
and for LAMR1, 50-GCGCGAATTCGCCATGTCCGGAGCC
CTTGAT-30 (forward primer) and 50-GCGCCTCGAGAGA
CAGTCAGTGGTTGCTCC-30 (reverse primer). The amplified
PCR products were digested and ligated into an EcoRI/
XhoI-digested pcDNA3.1zeo vector, which contained either
full-length Venus yellow fluorescent protein (vYFP) or the
N- or C-terminal regions (Yn or Yc, respectively) of vYFP or
full-length mCherry. Cysteine mutations were introduced by
site-directed mutagenesis (QuikChange, Stratagene) using the
following primer sequences: for Gal-3C173A, 50-GAGAACAA
CAGGAGAGTCATTGTTGCCAATACAAAGCTGGATAATA
ACTG-30 (forward primer) and 50-CAGTTATTATCCAGCTTT
GTATTGGCAACAATGACTCTCCTGTTGTTCTC-30 (reverse
primer); for 37LRPC148A, 50-CCTACCTACCATTGCGCTGGCT
AACACAGATTCTCCTCTG-30 (forward primer) and 50-CAG
AGGAGAATCTGTGTTAGCCAGCGCAATGGTAGGTAGG-30
(reverse primer); and for 37LRPC163A, 50-TGGACATTGCCAT
CCCAGCCAACAACAAGGGAGCTC-30 (forward primer) and
50-GAGCTCCCTTGTTGTTGGCTGGGATGGCAATGTCCA-30
(reverse primer). Cells were grown on fibronectin-coated
12 mm glass coverslips and transfected at approximately 60%
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2 : 1 according to manufacturer’s instructions. In brief, pre-
formed DNA : TransIT complexes were added to the growth
medium for 4 h. Cells were then washed with growth
medium, and recombinant proteins expressed for 24 h before
fixing with 4% PFA and subsequent confocal analysis.
5.6. siRNA of galectin-3 and LAMR1
hBMECs were cultured as described and transfected with pre-
designed siGENOME SMARTpool (mix of four siRNAs
targeting one ORF) targeting LAMR1 (M-013303-01-0005),
galectin-3 (M-010606-02-0005) or ON-TARGETplus non-
targeting pool control siRNA (Dharmacon, Thermo Scientific).
Cells were transfected on day 1 with a final concentration of
37.5 nM siRNA using the DharmaFECT transfection reagents
(Dharmacon, USA). The inhibition of LAMR1 and Gal-3
expression was assessed at 48, 72 or 96 h post-transfection 3
by confocal analysis, quantitative polymerase chain reaction
(RT-qPCR) and immunoblot analysis. To determine transfec-
tion efficiency, non-transfected and siGLO-transfected cells
were analysed 1 day after transfection on a FACSCaliber
machine (Beckton–Coulter). All galectin-3 or LAMR1 confocal
imageswere acquired at the same resolution and scale, with the
same hardware/laser settings used to image untreated control
cells. Identical image manipulations were performed on all
images stained with the same antibody set.
5.7. qPCR analysis
hBMECs were washed twice with serum-free EndoPrime base
medium (PAA) and total RNA extracted using the RNeasy
mini kit (Qiagen) according to the manufacturer’s instructions.
DNA was removed using RNAase-free turbo-DNAase I
(Ambion, Applied Biosystem). RNAwas cleaned and concen-
trated using RNeasy MiniElute clean-up kit (Qiagen). cDNA
was synthesized using high-capacity cDNA reverse transcrip-
tion kit (Applied Biosystems). RT-qPCR was performed in an
ABI7500 real-time PCR system (Applied Biosystems) with the
brilliant SYBR green qPCR master mix (Stratagene). Cycling
was initiated at 958C for 10 min, followed by 40 cycles of
958C for 15 s, 608C for 60 s and 608C for 1 min. Samples were
run in triplicate, and relative expression of LAMR1 and galec-
tin-3 was calculated using the comparative threshold cycle
method normalized to GAPDH. Primers were designed
using PRIMER 3 software and obtained from Sigma-Aldrich.
Primer sequences were as follows: GAPDH, 50-GGGAAAC
TGTGGCGTGAT-30 (forward primer) and 50-TTCAGCTCAG
GGATGACCTT-30 (reverse primer); LAMR1, 50-CCATTGAAA
ACCCTGCTGAT-30 (forward primer) and 50-CAGCGCA
ATGGTAGGTAGGT-30 (reverse primer); and galectin-3,
50-CTATAGCCGGGACTCCTTCC-30 (forward primer) and
50-AGTTCCAGGGCACATACGTC-30 (reverse primer).
5.8. Purification of recombinant protein
Cells from 50 ml culture were re-suspended in 5 ml of buffer
B (8 M urea (Sigma), 0.1 M NaH2PO4 (BDH) and 0.01 M Tris–
HCl (Sigma) pH 8.0) and then sonicated in an ice bath for 15
cycles of 10 s with 5 s of cooling between cycles. Lysate was
centrifuged at 10 000g for 30–40 min at 48C to pellet cellular
debris, followed by incubation of the supernatant with
20 mM imidazole (Qiagen) and cobalt resin (Fisher Scientific)overnight at 48C. Supernatant was passed through a gravity
column, extensively washed with buffer C (8 M urea, 0.1 M
NaH2PO4 and 0.01 M Tris–HCl, pH 6.3) and incubated over-
night at 48C with buffer E (8 M urea, 0.1 M NaH2PO4 and
0.01 M Tris–HCl, pH 4.5). Buffer exchange was performed
using PD-10 desalting columns (Amersham Biosciences),
replacing the acidic urea buffer with PBS (pH 7.2). Protein
concentration was measured using a Nanodrop ND-1000
spectrophotometer (NanoDrop Technologies) by measuring
the absorbance at 280 nm, and proteins were stored at2208C.
5.9. Immunoblotting
Cells were lysed with RIPA buffer supplemented with Phos-
stop (Merck Millipore) and complete mini EDTA-free
protease inhibitor cocktail. Alternatively, cells were fractio-
nated using a cell fractionation kit (Thermo Fisher
Scientific) as described in the manufacturer’s instructions.
Protein samples were separated on 4–20% gradient SDS–
PAGE (Thermo Scientific) at 125 V and calibrated with Col-
ourplus broad pre-stained marker. Gels were transferred to
nitrocellulose membranes (BioRad) at 10 V for 30 min on a
BioRad semi-dry transfer system. Membranes were blocked
in Tris-buffered saline with 0.1% Tween20 (TBS-T) containing
5% bovine serum albumin (BSA, w/v). Primary antibodies
(in TBS-T/5% BSA) were incubated with the membrane at
either 48C overnight or 1 h at room temperature. Membranes
were washed (3  15 min) in TBS-T and subsequently probed
with conjugated secondary antibody (in TBS-T/5% BSA) for
45 min at room temperature. The membrane was washed
(5  10 min) with TBS-T before membranes were exposed to
ECL substrate (Luminata Crescendo; Millipore) for visualiza-
tion of immuno-reactive proteins. Antibodies used included
anti-67LR (MLuC5), anti-37-kDa LAMR1 (A7 or IHLR) or
anti-Galectin-3 (9H3.2).
5.10. Modelling the molecular interaction of galectin-3
with LAMR1
The structures of the Gal-3 CRD and LAMR1 were obtained
from the RCSBprotein data bank (www.rcsb.org). Themolecu-
lar docking of Gal-3 (3zsj.pdb: lactose-liganded structure;
3zsm.pdb: non-liganded structure) and LAMR1 (3bch.pdb)
was performed employing a server in zdock.umassmed.edu
[60,61] based on current knowledge of crystal structures.
RASMOL [62] and UCSF CHIMERA [63] were used to generate
images of the molecular interactions and docking.
5.11. Bacterial strains, growth conditions and
invasion assays
Neisseria meningitidis clinical isolates (electronic supplementary
material, table S1) were grown on chocolate horse blood
(Oxoid) at 378C, in an atmosphere of 5% CO2. Mutagenesis of
N. meningitidis MC58 pilQ and porAwas described previously
[7]. To mutate pilE, chromosomal DNA extracted from
N. meningitidis C311DpilE (kindly provided by Prof. C. Tang,
University of Oxford, UK) was used to mutate MC58 by natu-
ral transformation and allelic exchange as described previously
[64]. The MC58DlgtF strain used in this study was described
previously [65]. For selection of mutants, meningococcal cells
were cultured on Mueller–Hinton agar plates supplemented
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mycin and spectinomycin (100 mg ml21) or kanamycin
(50 mg ml21). Invasion assays were performed as previously
described [66].
5.12. Expression and purification of recombinant LAMR1
The 37LRP coding sequence was generated with flanking NdeI
and NotI restriction sites using the following primer sequences
50-GGGAATTCCATATGGAGGTGCTATTCCAGGGACCCGG
ATCCATGTCCGGAGCCCTTGAT-30 (forward primer) and
50-AAGGAAAAAAGCGGCCGCTTAAGACCAGTCAGTGG
TTGCT-30 (reverse primer). The amplified PCR product was
NdeI/NotI digested and ligated into ss-Fc-IRES-Tpz-pEFBOS
[67], allowing the expression of N-terminally Fc-tagged
37LRP. Mutations were introduced by site-directed mutagen-
esis (QuikChange, Stratagene) using the following primer
sequences: for 37LRPR155A, 50-TAACACAGATTCTCCTCTG
GCCTATGTGGACATTGCCATC-30 (forward primer) and 50-
GATGGCAATGTCCACATAGGCCAGAGGAGAATCTGTGT
TA-30 (reverse primer); for 37LRPK166A, 50-CCATCCCATGCA
ACAACGCGGGAGCTCACTCAGTGG-30 (forward primer)
and 50-CCACTGAGTGAGCTCCCGCGTTGTTGCATGGAT
GG-30 (reverse primer); and for 37LRPY139F, 50-CCTCTCACGG
AGGCATCTTTTGTTAACCTACCTA-30 (forward primer) and
50-TAGG TAGGTTAACAAAAGATGCCTCCGTGAGAGG-30
(reverse primer). Recombinant 37LRP was expressed in
human embryonic kidney (HEK293T) cells grown in DMEM
(Gibco) supplemented with 1% (v/v) antibiotic/antimycotic
solution, 10% (v/v) FBS and 0.5% L-glutamine (Sigma). Trans-
fection was achieved using CaPO4 precipitation. Briefly,
DNA/CaCl2 mix was added to an equal volume of 2 
HEPES-buffered saline (pH 7.12), incubated for 10 min at
room temperature, and then added to approximately 40% con-
fluent HEK293T monolayers. After overnight incubation, the
medium was replaced with Ultra CHO cell medium (Gibco)
and cells incubated for a further 48 h. Cells were lysed with
RIPA buffer (supplemented with Phosstop (Merck Millipore)
and complete Mini EDTA-free protease inhibitor cocktail) and
cell debris removed by centrifugation at 20 000g for 10 min at
48C. Recombinant 37LRP was then purified by protein A affi-
nity chromatography using HiTrap protein A–sepharose HP
columns and the AKTA PrimePlus purification system, accord-
ing to the manufacturer’s instructions (GE Healthcare,
Amersham, UK). Briefly, the clarified lysate was mixed with
an equal volume of binding buffer, containing 20 mM sodium
phosphate and 150 mM NaCl (pH 7.3), and then applied to
the column. After washing unbound proteins, using the same
buffer, 37LRP was eluted using 0.1 M glycine (pH 2.5), andthe pH neutralized with 1 M Tris–HCl (pH 8.8). Eluted
proteins were then dialysed into PBS.
5.13. Enzyme-linked immunosorbant assays
100 ml lactose-purified recombinant human Gal-3 (Calbiochem)
or BSA (5 mg ml21) in PBS was used to coat amino-reactive
96-well microtiter plates (Immobilizer Amino; Nunc) over-
night at 48C. Bacterial strains were grown in liquid culture,
washed and labelled with digoxigenin (Roche) as descri-
bed previously [51]. Labelled bacteria were added to ELISA
plates for 2–4 h at room temperature. Plates were washed
with PBS/T and incubated with 100 ml polyclonal anti-digoxi-
genin Fab fragment–alkaline phosphatase antibody (1 : 5000;
Roche) in PBS/1% BSA for 1 h, and then washed several
times as described above. 100 ml of alkaline phosphatase sub-
strate (5 mg ml21; Roche) was added to each well, and the
absorbance measured at 405 nm after 15 min using an ELISA
reader (Biotek EL800). Inhibition assays were performed as
described above, except that bacteria were pre-incubated
with lactose or sugars for 2 h at room temperature before
being added. For LamR/Gal-3 binding, 100 ml aliquots of
8.7 mg ml21 37LRP proteins were immobilized as above.
Following washing in PBS/T, wells were blocked with 1%
BSA/PBS for 1 h. 100 ml of 5 mg ml21 Gal-3 was then added
and incubated at room temperature for 1 h. After washing,
100 ml of mouse anti-Gal-3 (9H3.2; 1 : 8000 diluted in 1%
BSA/PBS) was added and incubated at 48C overnight. After
washing, 100 ml anti-mouse IgG-HRP conjugate (1 : 8000
diluted in 1% BSA/PBS) was added and incubated at 48Cover-
night. Plates were again vigorously washed and colour
developed by adding 100 ml ABTS substrate (Roche). Plates
were read at an absorbance of 405 nm.
5.14. Cross-linking
Cross-linking was performed as described previously [41].
Briefly, N. meningitidis was incubated with Gal-3 conjugated
to the light-activated cross-linker Sulfo-SBED. After photoac-
tivation, in which the reactive biotin moiety is transferred to
molecules in close proximity to the cross-linking agent, cells
were washed, lysed, subjected to SDS–PAGE and immuno-
blotting, and probed with streptavidin before molecules
were identified using MALDI-TOF.
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